2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, White Blood Cell Disorders, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

2248 Treatment-free remission in patients (pts) who received linvoseltamab (LINVO) for relapsed/refractory multiple myeloma (RRMM) in LINKER-MM1

Joshua Richter I, MD, Jing Christine Ye, M.D., MSc2, Nisha Joseph, MD3, James E. Hoffman, MD4, Attaya Suvannasankha, MD5, Mansi Ramesh Shah, MD6, Rajshekhar Chakraborty, MD7, Joseph Maly, MD8, Swathi Namburi, MD9, Ka Lung Wu, MD, PhD10, Quang Nguyen11, Tito Roccia, MD12, Dhruti Chokshi13, Megan Seraphin, PharmD14, Steven Quatela15, Glenn Kroog16, Naresh Bumma, MD17
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
4 University of Miami Health System, Miami, Florida, United States
5 Indiana University Simon Cancer Center and Richard L. Roudebush VA Medical Center, Indianapolis, Indiana, United States
6 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
7 Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, New York, United States
8 Norton Cancer Institute, Louisville, Kentucky, United States
9 Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, Washington, United States
10 Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
11 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
12 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
13 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
14 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
15 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
16 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
17 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Introduction

LINVO, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, demonstrated high rates of durable responses with a generally manageable safety profile in pts with RRMM at the 200 mg dose in the pivotal LINKER-MM1 study (NCT03761108). In its current indication, LINVO treatment is recommended to continue until disease progression or unacceptable toxicity. However, it is unclear whether all pts require prolonged, continuous treatment to maintain disease response. Here, we present a post hoc analysis to evaluate outcomes of pts from LINKER-MM1 with sustained, durable responses after discontinuing LINVO for reasons other than disease progression.

Methods

LINKER-MM1 is an open-label, Phase 1/2 study of LINVO in adults with triple-class exposed (proteasome inhibitor, immunomodulatory drug, and an anti-C38 antibody) RRMM. Pts received intravenous LINVO once a week through Week 14 (Phase 2) or Week 16 (Phase 1), then once every 2 weeks; dosing frequency was decreased to once every 4 weeks for pts in Phase 2 with very good partial response or better (≥VGPR) and ≥24 weeks of treatment at the 200-mg full dose.

This subgroup analysis considered all dosing cohorts from the overall LINKER-MM1 population (N=282) and included pts who discontinued treatment for reasons other than progressive disease and who had a durable, treatment-free remission period (defined as partial response or better [≥PR] per investigator assessment, sustained for ≥90 days from last dose of LINVO at the time of data cut-off [DCO]). For analysis of efficacy, once the follow-up (FU) period was terminated by study discontinuation, pts were no longer followed for disease response.

Results

At DCO of Feb 17, 2026, 32 pts (LINVO 3 mg [n=1], 50 mg [n=13], 200 mg [n=17], and 400 mg [n=1]) met the criteria for this subgroup analysis. At baseline, these pts had a median (range) age of 66.0 years (45.0–81.0), 65.6% were female, and 18.8% were Black/African American. Consistent with the overall LINKER-MM1 200-mg population (n=117; approved full dose), over half of the pts in this subgroup analysis had Revised International Staging System stage II disease (56.3%; 55.6% in 200-mg overall population) and had standard cytogenetic risk (65.6%; 60.7%); median (range) bone marrow plasma cell percentage (20.0% [1–100]) was also similar to that observed in the overall 200-mg population (22.5% [1.0–100]). Additionally, most pts did not have extramedullary plasmacytomas (EMPs) at baseline (EMP-negative, 96.9%; 85.5% in overall 200-mg population) and had lower median (range) soluble BCMA concentrations (200.0 [18.7–3080.0] ng/mL) than the overall 200-mg population (376.50 [18.7–4430.0] ng/mL).

The median (range) duration of on-study FU, including both the on-treatment and safety/efficacy FU periods, was 36.5 months (9.0–67.4); 84.4% of pts had ≥20 months of on-study FU. Median (range) duration of treatment exposure was 74.9 weeks (8–175), with a median (range) of 32.5 doses (6–76) administered. All pts achieved a best overall response (BOR) of ≥VGPR, with 81.3% achieving complete response or better. Two pts did not achieve a ≥PR response prior to treatment discontinuation but later achieved a BOR of ≥VGPR during FU. The most common reasons for discontinuing LINVO were physician decision (43.8%) and adverse events (34.4%). Responses were sustained throughout the off-treatment FU period in 28/32 (87.5%) of pts; 4 pts discontinued the study due to disease progression while off treatment. Overall, pts remained in treatment-free remission for a median (range) of 12.7 months (3.0–36.4), with treatment-free remission lasting ≥6 months in 87.5% of pts.

Conclusions

This subgroup analysis of LINKER-MM1 demonstrated that pts with RRMM who achieved deep responses (≥VGPR) on LINVO therapy were able to sustain durable, prolonged periods of disease remission following treatment discontinuation, with over half of these pts maintaining response at ≥12 months after stopping LINVO. The majority of responses are ongoing. These findings suggest that if LINVO is discontinued, the majority of pts will continue to experience long periods of remission. While at this time there is no evidence to suggest that pts with RRMM should discontinue LINVO if treatment is tolerated, extended interval and fixed duration dosing strategies using a response-adapted approach are being explored in clinical trials in multiple myeloma and other plasma cell dyscrasias. Updated data will be presented at the meeting.

Joshua Richter I, MD: Menarini Stemline - Honoraria; Bristol Myers Squibb - Honoraria; Celgene - Honoraria; Forus - Honoraria; Sanofi - Honoraria; Karyopharm - Honoraria; Janssen - Honoraria; Pfizer - Honoraria; Regeneron Pharmaceuticals, Inc. - Honoraria; Janssen - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)